Swiss healthcare giant, dual pharma/diagnostics, global operations
Weight-loss GLP-1 drugs are expanding beyond injections to pills in the US, UK and UAE. Major manufacturers report rising uptake and ongoing development, with Medicare and NHS access shaping pace and affordability. Private prescriptions and new formulations are widening access while competition accelerates.
Swiss voters have rejected the Swiss People’s Party initiative to cap the country’s population at 10 million by 2050, with roughly 55% voting against and 45% in favour. The measure would have forced stricter asylum and family-reunification rules once population hit 9.5 million and could have ended free movement with the EU if the 10 million limit were breached.